Background/Aim: Rhabdomyolysis is associated with the release of myoglobin into the circulation, promoting acute kidney injury (AKI). In severe rhabdomyolysis, dialysis-dependent AKI doubles mortality. Standard blood purification techniques have limited efficacy in removing myoglobin. We describe high cut-off (HCO) renal replacement therapy (RRT) as a novel approach for extracorporeal elimination of myoglobin in rhabdomyolysis-associated AKI. Methods: With an in vivo molecular cut-off at 45 kDa, HCO filters are effective in removing myoglobin (17.8 kDa). Clearances across standard and HCO filters using continuous or intermittent RRT are reviewed in a case series of 11 patients with severe rhabdomyolysis and dialysis-dependent AKI. Results: Median myoglobin clearance across standard high-flux filters was 3.3 (interquartile range 2.3–3.9) ml/min for sustained low-efficiency daily dialysis (SLEDD) batch hemodialysis (HD) and 3.7 (2.9–6.7) ml/min for conventional HD. Respective clearances using HCO filters (membrane surface area: 1.1 m2) were 21.7 (20.3–26.1) ml/min (SLEDD) and 44.2 (41.3–47.0) ml/min (HD). Corrected for filter size, up to 20-fold higher clearances were obtained using HCO filters, resulting in profound and sustained reduction of plasma myoglobin concentration. Conclusions: As a novel approach, HCO RRT allows for rapid and effective removal of myoglobin from the circulation. In light of the pathogenic role in AKI, reducing exposure of the kidney to myoglobin may improve renal recovery and patient outcome. Our data pave the way for prospective trials, addressing this issue.

Keywords:
High cut-off filter, Acute kidney injury, Hemodialysis, Myoglobin, Renal replacement therapy, Rhabdomyolysis
1.
Bosch X, Poch E, Grau JM: Rhabdomyolysis and acute kidney injury. N Engl J Med 1996;361:62–67.
2.
Huerta-Alardín AL, Varon J, Marik PE: Bench-to-bedside review: rhabdomyolysis – an overview for clinicians. Crit Care 2005;9:158–169.
3.
Warren JD, Blumbergs PC, Thompson PD: Rhabdomyolysis: a review. Muscle Nerve 2002;25:332–347.
4.
Holt SG, Moore KP: Pathogenesis and treatment of renal dysfunction in rhabdomyolysis. Intensive Care Med 2001;27:803–811.
5.
Ward MM: Factors predictive of acute renal failure in rhabdomyolysis. Arch Intern Med 1998;148:1553–1557.
6.
Melli G, Chaudhry V, Cornblath DR: Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore) 2005;84:377–385.
7.
De Meijer AR, Fikkers BG, de Keijzer MH, van Engelen BG, Drenth JP: Serum creatine kinase as predictor of clinical course in rhabdomyolysis: a 5-year intensive care survey. Intensive Care Med 2003;29:1121–1125.
8.
Woodrow G, Brownjohn AM, Turney JH: The clinical and biochemical features of acute renal failure due to rhabdomyolysis. Ren Fail 1995;17:467–474.
9.
Zager RA, Gamelin LM: Pathogenetic mechanisms in experimental hemoglobinuric acute renal failure. Am J Physiol 1989;256:F446–F455.
10.
Reeder BJ, Wilson MT: Hemoglobin and myoglobin associated oxidative stress: from molecular mechanisms to disease states. Curr Med Chem 2005;12:2741–2751.
11.
Holt S, Reeder B, Wilson M, Harvey S, Morrow JD, Roberts LJ 2nd, Moore K: Increased lipid peroxidation in patients with rhabdomyolysis. Lancet 1999;353:1241.
12.
Zager RA: Studies of mechanisms and protective maneuvers in myoglobinuric acute renal injury. Lab Invest 1989;60:619–629.
13.
Wakabayashi Y, Kikuno T, Ohwada T, Kikawada R: Rapid fall in blood myoglobin in massive rhabdomyolysis and acute renal failure. Intensive Care Med 1994;20:109–112.
14.
Ronco C: Extracorporeal therapies in acute rhabdomyolysis and myoglobin clearance. Crit Care 2005;9:141–142.
15.
Gunal AI, Celiker H, Dogukan A, Ozalp G, Kirciman E, Simsekli H, Gunay I, Demircin M, Belhan O, Yildirim MA, Sever MS: Early and vigorous fluid resuscitation prevents acute renal failure in the crush victims of catastrophic earthquakes. J Am Soc Nephrol 2004;15:1862–1867.
16.
Ron D, Taitelman U, Michaelson M, Bar-Joseph G, Bursztein S, Better OS: Prevention of acute renal failure in traumatic rhabdomyolysis. Arch Intern Med 1984;144:277–280.
17.
Vanholder R, Sever MS, Erek E, Lameire N: Rhabdomyolysis. J Am Soc Nephrol 2000;11:1553–1561.
18.
Hart PM, Feinfeld DA, Briscoe AM, Nurse HM, Hotchkiss JL, Thomson GE: The effect of renal failure and hemodialysis on serum and urine myoglobin. Clin Nephrol 1982;18:141–143.
19.
Szpirt WM: Plasmapheresis is not justified in treatment of rhabdomyolysis and acute renal failure. J Cardiovasc Surg 1997;38:557.
20.
Bellomo R, Daskalakis M, Parkin G, Boyce N: Myoglobin clearance during acute continuous hemodiafiltration. Intensive Care Med 1991;17:509.
21.
Amyot SL, Leblanc M, Thibeault Y, Geadah D, Cardinal J: Myoglobin clearance and removal during continuous venovenous hemofiltration. Intensive Care Med 1999;25:1169–1172.
22.
Schenk MR, Beck DH, Nolte M, Kox WJ: Continuous veno-venous hemofiltration for the immediate management of massive rhabdomyolysis after fulminant malignant hyperthermia in a bodybuilder. Anesthesiology 2001;94:1139–1141.
23.
Zweigart C, Neubauer M, Storr M, Boehler T, Krause B: Progress in the development of membranes for kidney-replacement therapy; in Drioli E, Giorno L (eds): Comprehensive Membrane Science and Engineering. Oxford, Academic Press, 2010, vol 2, pp 351–390.
24.
Naka T, Jones D, Baldwin I, Fealy N, Bates S, Goehl H, Morgera S, Neumayer HH, Bellomo R: Myoglobin clearance by super-high-flux hemofiltration in a case of severe rhabdomyolysis: a case report. Crit Care 2005;9:R90–R95.
25.
Sorrentino SA, Kielstein JT, Lukasz A, Sorrentino JN, Gohrbandt B, Haller H, Schmidt BM: High permeability dialysis membrane allows effective removal of myoglobin in acute kidney injury resulting from rhabdomyolysis. Crit Care Med 2011;39:184–186.
26.
Heyne N, Guthoff M, Weisel KC: Rhabdomyolysis and acute kidney injury. N Engl J Med 2009;361:1412.
27.
Premru V, Kovač J, Buturović-Pionikvar J, Ponikvar R: High cut-off membrane hemodiafiltration in myoglobinuric acute renal failure: a case series. Ther Apher Dial 2011;15:287–291.
28.
Haase M, Bellomo R, Morgera S, Baldwin I, Boyce N: High cut-off point membranes in septic acute renal failure: a systematic review. Int J Artif Organs 2007;30:1031–1041.
29.
Uchino S, Bellomo R, Morimatsu H, Goldsmith D, Davenport P, Cole L, Baldwin I, Panagiotopoulos S, Tipping P, Morgera S, Naumayer HH, Goehl H: Cytokine dialysis: an ex vivo study. ASAIO J 2002;48:650–653.
30.
Hutchison CA, Harding S, Mead G, Goehl H, Storr M, Bradwell A, Cockwell P: Serum free-light chain removal by high cut-off hemodialysis: optimizing removal and supportive care. Artif Organs 2008;32:910–917.
31.
Weisel KC, Heyne N, Hutchison CA, Göhl H, Risler T, Kanz L: Effective light chain elimination via a high cut-off protein permeable filter in patients with light chain myeloma disease. Onkologie 2007;30(suppl 3):80.
32.
Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J, Hattersley J, Evans ND, Chappell MJ, Cook M, Goehl H, Storr M, Bradwell AR: Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007;18:886–895.
33.
Hutchison CA, Patel K, Whitehouse T: Early survival and duration of hospital admission in rhabdomyolysis: ICNARC Case Mix Programme Database. Crit Care 2011;15:452.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.